Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/10/2018
SIETES contiene 92571 citas

 
 
 1 a 20 de 1469 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
2. Cita con resumen
Bakhriansyah M, Souverein PC, de Boer A, Klungel OH. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case–control study. Pharmacoepidemiol Drug Saf 2017;26:1141-8. [Ref.ID 102084]
3.Enlace a cita original Cita con resumen
Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, Rojas-Fernández C, Walsh K, Welch V, Moayyedi P. Deprescribing proton pump inhibitors. Evidence-based clinical practice guideline. Canadian Family Physician - Le Médecin de Famille Canadien 2017;63:354-64. [Ref.ID 101592]
4. Cita con resumen
Gisbert JP, Molina-Infante J. Tratamiento actual de la infección por Helicobacter pylori. Med Clin (Barc) 2017;148:20-2. [Ref.ID 101339]
6. Cita con resumen
Anónimo. Comparative effectiveness of proton pump inhibitors. Therapeutics Initiative Evidence Based Drug Therapy 2016;99:1-2. [Ref.ID 100573]
7. Cita con resumen
Jones MG, Tsega S, Cho HJ. Inappropriate prescription of proton pump inhibitors in the setting of steroid use: a teachable moment. JAMA Intern Med 2016;176:594-5. [Ref.ID 100256]
8.Tiene citas relacionadas Cita con resumen
Li B-Z, Threapleton DE, Wang JY, Xu J-M, Yuan J-Q, Zhang C, Li P, Ye Q-L, Guo B, Mao C, Ye DQ. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 2015;351:h4052. [Ref.ID 99413]
9.Tiene citas relacionadas Cita con resumen
Braden B. The best and worst treatments for Helicobacter pylori. BMJ 2015;351:h4146. [Ref.ID 99411]
10.Enlace a cita original Cita con resumen
Anónimo. Prescripción razonada de IBP. Bolcan. Boletín Canario de Uso Racional del Medicamento del SCS 2015;7:1-8. [Ref.ID 99272]
11. Cita con resumen
Sung JJY, Suen B-Y, Wu JCY, Lau JYW, Ching JYL, Lee VWL, Chiu PWY, Tsoi KKF, Chan FKL. Effects of intravenous and oral esomeprazole in the prevention of recurrent bleeding from peptic ulcers after endoscopic therapy. Am J Gastroenterol 2014;109:1005-10. [Ref.ID 97601]
13. Cita con resumen
Bateman BT, Bykov K, Choudhry NK, Schneeweiss S, Gagne JJ, Polinski JM, Franklin JM, Doherty M, Fischer MA, Rassen JA. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ 2013;347:13. [Ref.ID 96347]
14.Tiene citas relacionadas Cita con resumen
Rothwell PM. Alternate-day, low-dose aspirin and cancer risk. Ann Intern Med 2013;159:148-50. [Ref.ID 95866]
15.Tiene citas relacionadas Cita con resumen
Cook NR, Lee I-M, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013;159:77-85. [Ref.ID 95862]
16. Cita con resumen
Lau JYW, Barkun A, Fan D-m, Ruipers EJ, Yang Y-s, Chan FK. Challenges in the management of acute peptic ulcer bleeding. Lancet 2013;381:2033-43. [Ref.ID 95609]
18.Tiene citas relacionadas Cita con resumen
Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Buttò V, Ferrucci L, Bandinelli S, Abbatecola AM, Spazzafumo L, Lattanzio F. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med 2013;173:518-23. [Ref.ID 95257]
19. Cita con resumen
Anónimo. Bismuth + métronidazole + tétracycline. Prescrire 2013;33:92-6. [Ref.ID 94872]
20.Enlace a cita original
Dworzynski K, Pollit V, Kelsey A, Higgins B, Palmer K, on behalf of the Guideline Development Group. Management of acute upper gastrointestinal bleeding: summary of NICE guidance. BMJ 2012;344:45-7. [Ref.ID 93219]
Seleccionar todas
 
 1 a 20 de 1469 siguiente >>